Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adagene Inc ADR (NQ: ADAG )

2.950 +0.240 (+8.86%)
Streaming Delayed Price Updated: 3:57 PM EDT, Aug 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,188,677
Open 2.580
Bid (Size) 2.900 (10)
Ask (Size) 3.050 (10)
Prev. Close 2.710
Today's Range 2.470 - 3.200
52wk Range 1.100 - 4.380
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Adagene Reports Six Month Financial Results for 2024 and Provides Corporate Update
From Adagene Inc.
Via GlobeNewswire
Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in September
From Adagene Inc.
Via GlobeNewswire

Performance

YTD
+50.51%
+50.51%
1 Month
+7.86%
+7.86%
3 Month
+14.34%
+14.34%
6 Month
-9.79%
-9.79%
1 Year
+144.85%
+144.85%

More News

Read More
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Adagene to Present at Investor Conferences in June
From Adagene Inc.
Via GlobeNewswire
How Is The Market Feeling About Adagene?
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update
From Adagene Inc.
Via GlobeNewswire
Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board
From Adagene Inc.
Via GlobeNewswire
Adagene to Present at the Leerink Partners Global Biopharma Conference 2024
From Adagene Inc.
Via GlobeNewswire
Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic
From Adagene Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Week in Review: Lee’s Pharma Signs $138 Million Agreement For China Rights To Heart Failure Therapy
Via Talk Markets
Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Why Airspan Networks Shares Are Trading Higher By Over 380%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why Is Cancer Focused Adagene Stock Plummeting Today?
Via Benzinga
Why DatChat Shares Are Trading Lower By Around 33%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
From Adagene Inc.
Via GlobeNewswire
Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium
From Adagene Inc.
Via GlobeNewswire
Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023
From Adagene Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.